<unk>  (Sovaldi) 400mg Initial HCV treatment In 2016, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America jointly published a recommendation for the management of hepatitis C. In this recommendation,<unk>  used in combination with other drugs is part of all first-line treatments for HCV genotypes 1, 2, 3, 4, 5, and 6, and is also part of some second-line treatments.<unk>  in combination with velpatasvir is recommended for all genotypes with a cure rate greater than 90%, and close to 100% in most cases. The duration of treatment is typically 12 weeks.<unk>  is also used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectiveness–based perspective. For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections,<unk>  can be used in combination with the viral NS5A inhibitor ledipasvir. In genotype 2 and 3 HCV infections,<unk>  can be used in combination with daclatasvir. For the treatment of cases with cirrhosis or liver transplant patients, weight-based ribavirin is sometimes added. Peginterferon with or without<unk>  is not recommended in an initial HCV treatment. Compared to previous treatments,<unk> -based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduction in therapy duration.<unk>  allows most people to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of hepatitis C virus. Prior failed treatment For people who have experienced treatment failure with some form of combination therapy for hepatitis C infection, one of the next possible steps would be retreatment with<unk>  and either ledipasvir or daclatasvir, with or without weight-based ribavirin. The genotype and particular combination therapy a person was on when the initial treatment failed are also taken into consideration when deciding which combination to use next. The duration of retreatment can range from 12 weeks to 24 weeks depending on several factors, including which medications are used for the retreatment, whether the person has liver cirrhosis or not, and whether the liver damage is classified as compensated cirrhosis or decompensated cirrhosis. Pregnancy and breastfeeding No adequate human data are available to establish whether or not<unk>  poses a risk to pregnancy outcomes. However, ribavirin, a medication that is often given together with<unk>  to treat hepatitis C, is assigned a Pregnancy Category X (contraindicated in pregnancy) by the FDA. Pregnant women with hepatitis C who take ribavirin have shown some cases of birth defects and death in their fetus. It is recommended that<unk> /ribarivin combinations be avoided in pregnant females and their male sexual partners in order to reduce harmful fetal defects caused by ribavirin. Females who could potentially become pregnant should undergo a pregnancy test 2 months prior to starting the<unk> /ribavirin/peginterferon combination treatment, monthly throughout the duration of the treatment, and six months post-treatment to reduce the risk of fetal harm in case of accidental pregnancy. It is unknown whether<unk>  and ribavirin pass into breastmilk; therefore, it is recommended that the mother does not breastfeed during treatment with<unk>  alone or in combination with ribavirin.
Sofosbuvir
Dasabuvir
Telaprevir
Fosamprenavir
Enfuvirtide
Coronavir
Abacavir
Indinavir